Title |
Neuro-oncology biotech industry progress report
|
---|---|
Published in |
Journal of Neuro-Oncology, February 2016
|
DOI | 10.1007/s11060-016-2087-z |
Pubmed ID | |
Authors |
Shamik Chakraborty, Imithri Bodhinayake, Amrit Chiluwal, David J. Langer, Rosamaria Ruggieri, Marc Symons, John A. Boockvar |
Abstract |
The Brain Tumor Biotech Center at the Feinstein Institute for Medical Research, in collaboration with Voices Against Brain Cancer hosted The Brain Tumor Biotech Summit at in New York City in June 2015. The focus was once again on fostering collaboration between neuro-oncologist, neurosurgeons, scientists, leaders from biotechnology and pharmaceutical industries, and members of the financial community. The summit highlighted the recent advances in the treatment of brain tumor, and specifically focused on targeting of stem cells and EGFR, use of prophage and immunostimulatory vaccines, retroviral vectors for drug delivery, biologic prodrug, Cesium brachytherapy, and use of electric field to disrupt tumor cell proliferation. This article summarizes the current progress in brain tumor research as presented at 2015 The Brain Tumor Biotech Summit. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 24 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 21% |
Student > Bachelor | 3 | 13% |
Student > Ph. D. Student | 3 | 13% |
Student > Doctoral Student | 2 | 8% |
Lecturer | 2 | 8% |
Other | 6 | 25% |
Unknown | 3 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 46% |
Neuroscience | 4 | 17% |
Agricultural and Biological Sciences | 1 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Earth and Planetary Sciences | 1 | 4% |
Other | 1 | 4% |
Unknown | 5 | 21% |